We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ASCT

News List

NICE recommends Revlimid for newly diagnosed multiple myeloma patients pharmatimes
January 27, 2021
Bristol Myers Squibb’s (BMS) Revlimid (lenalidomide) has received a recommendation from the UK’s National Institute of Health and Care Excellence (NICE) for newly diagnosed multiple myeloma patients.
ASCT May Offer Alternative for Tx of High-Risk Follicular Lymphoma drugs
July 26, 2019
Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk...
Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018 pharmafile
December 07, 2018
Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 data for its combination of Darzalex (daratumumab) alongside lenalidomide